Ignite Creation Date:
2025-12-24 @ 2:52 PM
Ignite Modification Date:
2026-01-07 @ 1:39 PM
Study NCT ID:
NCT06162559
Status:
RECRUITING
Last Update Posted:
2024-01-11
First Post:
2023-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Sponsor:
The Netherlands Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-18
Start Date Type:
ACTUAL
Primary Completion Date:
2026-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2036-05
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-29
First Submit QC Date:
None
Study First Post Date:
2023-12-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-09
Last Update Post Date:
2024-01-11
Last Update Post Date Type:
ACTUAL